Outcomes of teclistamab in RRMM with prior exposure to BCMA-directed therapy
Jack Khouri, MD, Cleveland Clinic, Cleveland, OH, comments on a study investigating the outcomes of teclistamab treatment in patients with relapsed/refractory multiple myeloma (RRMM) who had prior exposure to BCMA-directed therapy. Dr Khouri notes that patients with prior BCMA-targeted therapy had lower response rates to teclistamab, but this was improved if nine months were waited before teclistamab administration. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
